Related Experiment Videos
Expression of MAGE genes in osteosarcoma
1Department of Immunology, Kurume University School of Medicine, Japan.
Summary
MAGE genes, encoding tumor-rejection antigens, are expressed in human osteosarcomas. This expression occurs in a major histocompatibility class-I-restricted manner, suggesting potential for immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- MAGE genes encode tumor-rejection antigens.
- These antigens are recognized by cytotoxic T lymphocytes.
- Major histocompatibility complex (MHC) class-I molecules present antigens to T cells.
Purpose of the Study:
- To investigate MAGE gene expression in human osteosarcomas.
- To determine if MAGE antigens are presented in an MHC class-I-restricted manner.
Main Methods:
- Reverse transcription-polymerase chain reaction (RT-PCR) for mRNA expression.
- Immunoblot analysis for protein detection.
- Analysis of 20 osteosarcoma cell lines and eight fresh tumor tissues.
Main Results:
- MAGE-1, -2, -3, and -6 mRNA were detected in 52.4%, 47.6%, 47.6%, and 47.6% of cell lines, respectively.
- MAGE mRNA expression was also observed in fresh tumor tissues (ranging from 12.5% to 75%).
- MAGE-1 or MAGE-4 protein was detected in cell lines with corresponding mRNA expression; MHC class-I antigens were expressed in 90.5% of cell lines.
Conclusions:
- MAGE tumor-rejection antigens are expressed in a significant proportion of osteosarcomas.
- The expression of MAGE antigens in osteosarcomas is largely MHC class-I-restricted.
- These findings support the potential of MAGE antigens as targets for osteosarcoma immunotherapy.